Boao Lecheng Medical Tourism Zone Partners with Eye Valley to Advance Ophthalmology Innovation
The Boao Lecheng Medical Tourism Pilot Zone in Hainan Province has announced a strategic partnership...
Cellular Biomedicine Group Initiates Phase III Study for AlloJoin in Knee Osteoarthritis
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has announced the initiation of a...
Abbisko Therapeutics Secures Orphan Drug Designation for FGFR4 Inhibitor ABSK012
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received orphan...
Henlius Reports 91.1% Revenue Growth in 2022, Driven by Product Commercialization
China-based Henlius (HKG: 2696) has announced its annual results for 2022, revealing that revenues reached...
Everest Medicines Reports 2022 Revenue Growth and Pipeline Updates
China-based Everest Medicines (HKG: 1952) has released its financial report for 2022, along with key...
ClouDr Partners with Banbiantian to Digitalize Medicine and Medical Device Sector
Hangzhou Kang Ming Information Technology Co., Ltd, trading under the name “ClouDr” (HKG: 9955), has...
Pharmaron Secures UK Government Grant to Expand Viral Vector Manufacturing Facility
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759)...
HutchMed Completes NDA Submission to US FDA for Frquintinib in Metastatic CRC
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced the completion of a rolling...
Apollomics Inc. Completes Merger with Maxpro Capital, Lists on NASDAQ as ‘APLM’
Sino-US biotech firm Apollomics Inc. has announced the successful completion of a merger with the...
Huadong Medicine Wins NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...
Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership
Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...
Fosun Pharmaceutical Gets NMPA Approval for FCN-159 Phase II Study in LCH
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that it has...
Shanghai Fosun Pharma Commences Phase III Trial for HER2-Targeted FS-1502
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a prominent Chinese pharmaceutical company,...
Kangtai Bio Partners with AstraZeneca and Combiphar to Expand Vaccine Collaboration
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading Chinese vaccine manufacturer, has entered...
CStone Pharmaceuticals’ Sugemalimab Study Published in JCO for R/R ENKTL Treatment
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, announced that the Journal of Clinical Oncology...
IceCure Medical Gains NMPA Approval for Cryoablation Technology in China
Israel-based IceCure Medical (NASDAQ: ICCM) has announced that it has obtained regulatory approval from China’s...
SciNeuro Pharmaceuticals and Secarna Pharmaceuticals Ink CNS Disease Research Deal
China-based SciNeuro Pharmaceuticals and Germany’s Secarna Pharmaceuticals GmbH & Co. KG have announced a research...
Beijing’s QL Bio Secures Tens of Millions in Funding for Proteomics Platform Upgrade
QL Bio, a Beijing-based proteomics testing company, has reportedly secured tens of millions of renminbi...
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for...
Round 8 VBP Tender Results Announced with RMB 21.6 Billion Market
The National Allied Procurement Office has issued an initial notification upon the completion of Round...